Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in T2DM with CV Disease and Hypertension
NCT01031680Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Feb 2010; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01031680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031680.